BibTex RIS Cite

The effect of topical cyclosporine A on tear film instability in patients with posterior blepharitis

Year 2013, Volume: 40 Issue: 3, 446 - 448, 01.09.2013
https://doi.org/10.5798/diclemedj.0921.2013.03.0307

Abstract

Objective: The aim of this study is to evaluate the efficacy of topical cyclosporine A (CsA) 0.05% (Restasis, Allergan Pharmaceuticals) in patients with posterior blepharitis. Methods: The study included 15 patients with posterior blepharitis. Topical CsA 0.05% (Restasis, Allergan Pharmaceuticals) was applied twice a daily for 2 months. They were evaluated at baseline and after treatment for subjective symptoms and objective signs including tear breakup time (BUT), Schirmer scores, conjunctival hyperemia, tarsal telangiectasis and Meibomian gland inclusions. Results: Fifteen patients completed the study. At the 2-month visit, the patients showed improvement in ocular symptom including burning, itching, conjunctival hyperemia (p

References

  • Thygeson P. Etiology and treatment of blepharitis; a study in military personnel. Arch Ophthalmol 1946;36:445-457.
  • Moore CP. Immunomodulating agents. In: Ocular Therapeu- tics. Elsevier Inc. 2004;725–737.
  • Sall K, Stevenson OD, Mundorf TK et al. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000;107:631-639.
  • Secchi AG, Tognon MS, Leonardi A. Topical use of cyclo- sporine in the treatment of vernal keratoconjunctivitis Am J Ophthalmol 1990;110:641-645.
  • Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of li- pase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-1975.
  • Donshik P, Kulvin SM, Mckinley P, Skowron R. Treatment of chronic staphylococcal blepharoconjunctivitis with a new topical steroid anti-infective ophthalmic solution. Ann Ophthalmol 1983;15:162-167.
  • Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens 2003;29:96-99.
  • Foulks GN. Topical cyclosporine for treatment of ocular sur- face disease. Int Ophthalmol Clin 2006;46:105-122.
  • Salib G, McDonald M, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artifi cial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 2006;32:772–778.
  • Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004;111:476-482.
  • Hom MM. The use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Eye Contact Lens 2006;32:109-111.
  • Hill JC. The use of systemic cyclosporin a in human corneal transplantation: a preliminary report. Documenta Ophthal- mol 1986;62:337-344.
  • Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Ef- ficacy of commercially available topical cyclosporine a 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171-175.
  • Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther 2006;22:47-53.

Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi

Year 2013, Volume: 40 Issue: 3, 446 - 448, 01.09.2013
https://doi.org/10.5798/diclemedj.0921.2013.03.0307

Abstract

Amaç: Posterior blefaritli hastalarda topikal siklosporin A (CsA) tedavisinin etkinliğini değerlendirmek. Yöntemler: Posterior blefaritli 15 hasta çalışmaya dahil edildi. Hastalara 2 ay boyunca günde 2 kez topikal CsA %0.05 (Restasis, Allergan Pharmaceuticals) uygulandı. Hastalarda tedavi öncesi ve sonrası subjektif semptomlara ve gözyaşı kırılma zamanı (GKZ), Schirmer testi, konjonktival hiperemi, tarsal telenjiektazi ve meibomian bezi sekresyonuna bakıldı. Bulgular: 2 aylık takiplerde yanma, kaşıntı, konjonktival hiperemi semptomlarında azalma izlendi (Sırasıyla p

References

  • Thygeson P. Etiology and treatment of blepharitis; a study in military personnel. Arch Ophthalmol 1946;36:445-457.
  • Moore CP. Immunomodulating agents. In: Ocular Therapeu- tics. Elsevier Inc. 2004;725–737.
  • Sall K, Stevenson OD, Mundorf TK et al. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000;107:631-639.
  • Secchi AG, Tognon MS, Leonardi A. Topical use of cyclo- sporine in the treatment of vernal keratoconjunctivitis Am J Ophthalmol 1990;110:641-645.
  • Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of li- pase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-1975.
  • Donshik P, Kulvin SM, Mckinley P, Skowron R. Treatment of chronic staphylococcal blepharoconjunctivitis with a new topical steroid anti-infective ophthalmic solution. Ann Ophthalmol 1983;15:162-167.
  • Olson MC, Korb DR, Greiner JV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens 2003;29:96-99.
  • Foulks GN. Topical cyclosporine for treatment of ocular sur- face disease. Int Ophthalmol Clin 2006;46:105-122.
  • Salib G, McDonald M, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artifi cial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg 2006;32:772–778.
  • Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology 2004;111:476-482.
  • Hom MM. The use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Eye Contact Lens 2006;32:109-111.
  • Hill JC. The use of systemic cyclosporin a in human corneal transplantation: a preliminary report. Documenta Ophthal- mol 1986;62:337-344.
  • Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Ef- ficacy of commercially available topical cyclosporine a 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171-175.
  • Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther 2006;22:47-53.
There are 14 citations in total.

Details

Primary Language Turkish
Journal Section Research Articles
Authors

Onur Çatak This is me

Fatma Ülkü Çeliker This is me

Publication Date September 1, 2013
Submission Date March 2, 2015
Published in Issue Year 2013 Volume: 40 Issue: 3

Cite

APA Çatak, O., & Çeliker, F. Ü. (2013). Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi. Dicle Medical Journal, 40(3), 446-448. https://doi.org/10.5798/diclemedj.0921.2013.03.0307
AMA Çatak O, Çeliker FÜ. Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi. diclemedj. September 2013;40(3):446-448. doi:10.5798/diclemedj.0921.2013.03.0307
Chicago Çatak, Onur, and Fatma Ülkü Çeliker. “Posterior Blefaritli Hastalarda Topikal Siklosporin A Tedavisinin gözyaşı Film Instabilitesine Etkisi”. Dicle Medical Journal 40, no. 3 (September 2013): 446-48. https://doi.org/10.5798/diclemedj.0921.2013.03.0307.
EndNote Çatak O, Çeliker FÜ (September 1, 2013) Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi. Dicle Medical Journal 40 3 446–448.
IEEE O. Çatak and F. Ü. Çeliker, “Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi”, diclemedj, vol. 40, no. 3, pp. 446–448, 2013, doi: 10.5798/diclemedj.0921.2013.03.0307.
ISNAD Çatak, Onur - Çeliker, Fatma Ülkü. “Posterior Blefaritli Hastalarda Topikal Siklosporin A Tedavisinin gözyaşı Film Instabilitesine Etkisi”. Dicle Medical Journal 40/3 (September 2013), 446-448. https://doi.org/10.5798/diclemedj.0921.2013.03.0307.
JAMA Çatak O, Çeliker FÜ. Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi. diclemedj. 2013;40:446–448.
MLA Çatak, Onur and Fatma Ülkü Çeliker. “Posterior Blefaritli Hastalarda Topikal Siklosporin A Tedavisinin gözyaşı Film Instabilitesine Etkisi”. Dicle Medical Journal, vol. 40, no. 3, 2013, pp. 446-8, doi:10.5798/diclemedj.0921.2013.03.0307.
Vancouver Çatak O, Çeliker FÜ. Posterior blefaritli hastalarda topikal siklosporin A tedavisinin gözyaşı film instabilitesine etkisi. diclemedj. 2013;40(3):446-8.